News in brief
German court invalidates GSK Advair patent
A group of generic drug makers have won a patent challenge in a German court against GlaxoSmithKline’s asthma drug Advair
(fluticasone/salmeterol). The German Federal Patents Court ruling followed a hearing in February in which generic firms Mylan,
Neolab, Hexal – part of Novartis’ Sandoz unit and Ivax – a unit of Teva Pharmaceuticals challenged the patent on the combination
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.